ClinicalTrials.gg
CompletedNCT01955837TERRAUpdated Nov 17, 2020Results posted

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

A Phase 3 interventional study of TAS-102 and Placebo in Colorectal Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Otsuka Holdings Co., Ltd..

Enrollment
6th of 13
406 · median 107
Started
2013
with 1 other
Phase 3
4 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 11th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.

Read the detailed description

This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Has provided written
  • Has adenocarcinoma of the colon or rectum
  • Has failed at least 2 prior regimens of standard chemotherapies for colorectal cancer
  • (ECOG) performance status of 0 or 1
  • Is able to take medication orally
  • Has adequate organ function (bone marrow, kidney and liver)
  • Women of must have a negative pregnancy test and must agree to adequate if conception is possible. Males must agree to adequate birth control.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    TAS-102

    Drug: TAS-102

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTAS-102

    TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

  • DrugPlacebo

    Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

06

What researchers measure

Primary outcomes

  1. Overall Survival(OS)

    The primary endpoint was Overall Survival (OS), which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.

    Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.

Secondary outcomes

  1. Progression-free Survival (PFS)

    Tumor assessments were performed throughout the study period and analyzed using Response Evaluation Criteria in Solid Tumors criteria (Version 1.1, 2009). Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment.

    Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.

  2. Time to Treatment Failure (TTF)

    Time to treatment failure was defined as the time (in months) from the date of randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause. Censoring for TTF was also applied for those patients who were given non-study cancer treatment, with censoring at the time when the patient began the non-study cancer treatment.

    Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.

  3. Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)

    The assessment of ORR was based on Investigator review of the images according to RECIST Version 1.1. Overall response rate was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). At the analysis stage, the best overall response was assigned for each patient as the best response recorded from all responses recorded after study randomization. If applicable, responses recorded after disease progression or initiation of non-study cancer treatment was excluded. A patient's best response assignment of stable disease (SD) needed to be maintained for at least 6 weeks after study randomization. If a patient didn't meet this condition, best response was assigned "Not evaluable".

    Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.

  4. Disease Control Rate (DCR; CR, PR, or Stable Disease)

    The assessment of DCR paralleled that of ORR, with DCR defined as the proportion of patients with objective evidence of CR, PR, or SD.

    Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.

  5. Duration of Response

    Duration of response was derived for those patients with objective evidence of PR or CR. Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause. Patients alive and progression free as of the analysis cut-off date were censored at their last evaluable tumor response assessment prior to initiation of any non-study cancer treatment.

    Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.

  6. Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Adverse Events)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.

    Time frame: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.

  7. Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Laboratory Assessments)

    All laboratory values that were out of the normal range were to be evaluated for their clinical significance before exposing the patient to the next dose of study medication. Any laboratory abnormality that was clinically significant, e.g., results in delay of study medication dosing, study discontinuation, required treatment due to abnormal values, or was considered by the Investigator to be medical important, were to be reported as an AE, unless it was considered part of clinical manifestations to a clinical diagnosis that has already been reported as an AE.

    Time frame: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.

  8. Overall Survival(OS)(Wild Type KRAS)

    The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by wild type KRAS.

    Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.

  9. Overall Survival(OS)(Mutant Type KRAS)

    The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by mutant type KRAS.

    Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.

  10. Progression-free Survival (PFS) (Wild Type KRAS)

    Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by wild type KRAS.

    Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.

  11. Progression-free Survival (PFS) (Mutant Type KRAS)

    Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by mutant type KRAS.

    Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.

07

Results

Posted Nov 17, 2020

Participant flow

Participants were enrolled at 406 centers in China, the Republic of Korea and Thailand from 16 October 2013 to 15 June 2015.

Participant flow — Overall Study
MilestoneTAS-102(Trifluridine/Tipiracil)Placebo
Started271135
Completed271135
Not completed00

Outcome measures

PrimaryOverall Survival(OS)

The primary endpoint was Overall Survival (OS), which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.

Time frame:
Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Reported as:
Median · Months
Overall Survival(OS)
MonthsTAS-102(Trifluridine/Tipiracil)Placebo
Overall Survival(OS)7.8 (7.1 to 8.8)7.1 (5.9 to 8.2)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Log Rank · p = 0.035 · Hazard ratio (hr): 0.79 · 95% CI 0.62 to 0.99
SecondaryProgression-free Survival (PFS)

Tumor assessments were performed throughout the study period and analyzed using Response Evaluation Criteria in Solid Tumors criteria (Version 1.1, 2009). Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment.

Time frame:
Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsTAS-102(Trifluridine/Tipiracil)Placebo
Progression-free Survival (PFS)2.0 (1.9 to 2.8)1.8 (1.7 to 1.8)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.43 · 95% CI 0.34 to 0.54
SecondaryTime to Treatment Failure (TTF)

Time to treatment failure was defined as the time (in months) from the date of randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause. Censoring for TTF was also applied for those patients who were given non-study cancer treatment, with censoring at the time when the patient began the non-study cancer treatment.

Time frame:
From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsTAS-102(Trifluridine/Tipiracil)Placebo
Time to Treatment Failure (TTF)1.9 (1.9 to 2.2)1.8 (1.7 to 1.8)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.46 · 95% CI 0.37 to 0.58
SecondaryOverall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)

The assessment of ORR was based on Investigator review of the images according to RECIST Version 1.1. Overall response rate was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). At the analysis stage, the best overall response was assigned for each patient as the best response recorded from all responses recorded after study randomization. If applicable, responses recorded after disease progression or initiation of non-study cancer treatment was excluded. A patient's best response assignment of stable disease (SD) needed to be maintained for at least 6 weeks after study randomization. If a patient didn't meet this condition, best response was assigned "Not evaluable".

Time frame:
From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)
percentage of participantsTAS-102(Trifluridine/Tipiracil)Placebo
Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)1.1 (0.2 to 3.3)0.0 (0.0 to 2.8)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Fisher Exact · p = 0.554 · Difference in orr: 1.1 · 95% CI -0.1 to 2.4
SecondaryDisease Control Rate (DCR; CR, PR, or Stable Disease)

The assessment of DCR paralleled that of ORR, with DCR defined as the proportion of patients with objective evidence of CR, PR, or SD.

Time frame:
From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Reported as:
Number · percentage of participants
Disease Control Rate (DCR; CR, PR, or Stable Disease)
percentage of participantsTAS-102(Trifluridine/Tipiracil)Placebo
Disease Control Rate (DCR; CR, PR, or Stable Disease)44.1 (37.9 to 50.3)14.6 (9.0 to 21.9)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Fisher Exact · p = <0.001 · Difference in dcr: 29.4 · 95% CI 20.9 to 38.0
SecondaryDuration of Response

Duration of response was derived for those patients with objective evidence of PR or CR. Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause. Patients alive and progression free as of the analysis cut-off date were censored at their last evaluable tumor response assessment prior to initiation of any non-study cancer treatment.

Time frame:
From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Reported as:
Median · Months
Duration of Response
MonthsTAS-102(Trifluridine/Tipiracil)Placebo
Duration of Response6.6 (3.9 to 9.2)0 (0 to 0)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Fisher Exact · p = <0.001 · Odds ratio (or): 29.4 · 95% CI 20.9 to 38.0
SecondarySafety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Adverse Events)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.

Time frame:
From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
Reported as:
Count of participants · Participants
Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Adverse Events)
ParticipantsTAS-102(Trifluridine/Tipiracil)Placebo
No AEs215
One or more AEs269120
One or more TEAEs269118
TEAE severity by CTCAE grade:Grade12332
TEAE severity by CTCAE grade:Grade28441
TEAE severity by CTCAE grade:Grade312733
TEAE severity by CTCAE grade:Grade43011
TEAE severity by CTCAE grade:Grade551
TEAE causality(Related)24470
TEAE causality(Not Related)2548
One or more TEAEs leading to discontinuation2713
One or more SAEs6332
One or more TESAEs6331
One or more TEAEs leading to death51
SecondarySafety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Laboratory Assessments)

All laboratory values that were out of the normal range were to be evaluated for their clinical significance before exposing the patient to the next dose of study medication. Any laboratory abnormality that was clinically significant, e.g., results in delay of study medication dosing, study discontinuation, required treatment due to abnormal values, or was considered by the Investigator to be medical important, were to be reported as an AE, unless it was considered part of clinical manifestations to a clinical diagnosis that has already been reported as an AE.

Time frame:
From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
Reported as:
Count of participants · Participants
Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Laboratory Assessments)
ParticipantsTAS-102(Trifluridine/Tipiracil)Placebo
Anemia:Any Grade20952
Anemia:Grade >=3488
Leukopenia:Any Grade1904
Leukopenia:Grade >=3560
Neutropenia:Any Grade1821
Neutropenia:Grade >=3900
Lymphopenia:Any Grade14634
Lymphopenia:Grade >=3393
Thrombocytopenia:Any Grade9610
Thrombocytopenia:Grade >=382
Lymphocytosis:Any Grade41
Lymphocytosis:Grade >=310
Increase in alkaline phosphatase level:Any Grade9158
Increase in alkaline phosphatase level:Grade >=3115
Hyperglycemia:Any Grade9850
Hyperglycemia:Grade >=373
Increase in total bilirubin level:Any Grade9928
Increase in total bilirubin level:Grade >=31910
Hypoalbuminemia:Any Grade7844
Hypoalbuminemia:Grade >=380
Hyponatremia:Any Grade8138
Hyponatremia:Grade >=3126
Hypocalcemia:Any Grade7733
Hypocalcemia:Grade >=331
Increase in AST level:Any Grade6340
Increase in AST level:Grade >=3107
Increase in ALT level:Any Grade4829
Increase in ALT level:Grade >=334
Hypokalemia:Any Grade3111
Hypokalemia:Grade >=321
Increase in creatinine level:Any Grade1310
Increase in creatinine level:Grade >=330
Hyperkalemia:Any Grade1110
Hyperkalemia:Grade >=310
Hypercalcemia:Any Grade81
Hypercalcemia:Grade >=301
SecondaryOverall Survival(OS)(Wild Type KRAS)

The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by wild type KRAS.

Time frame:
Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Reported as:
Median · months
Overall Survival(OS)(Wild Type KRAS)
monthsTAS-102(Trifluridine/Tipiracil)Placebo
Overall Survival(OS)(Wild Type KRAS)8.6 (7.4 to 10.9)7.4 (5.6 to 9.2)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Log Rank · p = 0.083 · Hazard ratio (hr): 0.77 · 95% CI 0.57 to 1.04
SecondaryOverall Survival(OS)(Mutant Type KRAS)

The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by mutant type KRAS.

Time frame:
Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Reported as:
Median · months
Overall Survival(OS)(Mutant Type KRAS)
monthsTAS-102(Trifluridine/Tipiracil)Placebo
Overall Survival(OS)(Mutant Type KRAS)7.0 (5.4 to 8.0)6.5 (4.6 to 7.6)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Log Rank · p = 0.228 · Hazard ratio (hr): 0.83 · 95% CI 0.57 to 1.20
SecondaryProgression-free Survival (PFS) (Wild Type KRAS)

Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by wild type KRAS.

Time frame:
Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Reported as:
Median · months
Progression-free Survival (PFS) (Wild Type KRAS)
monthsTAS-102(Trifluridine/Tipiracil)Placebo
Progression-free Survival (PFS) (Wild Type KRAS)2.0 (1.9 to 3.4)1.8 (1.7 to 1.8)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Hazard ratio (hr): 0.44 · 95% CI 0.32 to 0.59
SecondaryProgression-free Survival (PFS) (Mutant Type KRAS)

Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by mutant type KRAS.

Time frame:
Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Reported as:
Median · Months
Progression-free Survival (PFS) (Mutant Type KRAS)
MonthsTAS-102(Trifluridine/Tipiracil)Placebo
Progression-free Survival (PFS) (Mutant Type KRAS)2.2 (1.9 to 3.4)1.8 (1.7 to 1.9)
Statistical analysis
  • TAS-102(Trifluridine/Tipiracil) vs Placebo · Hazard ratio (hr): 0.45 · 95% CI 0.31 to 0.65

Adverse events

Collected over Safety monitoring continued from the time a patient signed informed until 30 days after the last dose of study medication or until the initiation of another cancer therapy, whichever came first, up to 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAS-102205/271 (75.6%)63/271 (23.2%)269/271 (99.3%)
Placebo111/135 (82.2%)32/135 (23.7%)120/135 (88.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventTAS-102Placebo
IleusGastrointestinal disorders2/2714/135
AscitesGastrointestinal disorders1/2713/135
AnaemiaBlood and lymphatic system disorders5/2711/135
Bile duct obstructionHepatobiliary disorders0/2712/135
PneumoniaInfections and infestations2/2712/135
Decreased appetiteMetabolism and nutrition disorders0/2712/135
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2712/135
Small intestinal obstructionGastrointestinal disorders4/2711/135
Intestinal obstructionGastrointestinal disorders3/2711/135
PyrexiaGeneral disorders3/2710/135
Most frequent other events
Showing 10 of 35
Most frequent other events
EventTAS-102Placebo
AnaemiaBlood and lymphatic system disorders124/27127/135
NauseaGastrointestinal disorders104/27120/135
White blood cell count decreasedInvestigations102/2713/135
NeutropeniaBlood and lymphatic system disorders98/2712/135
Decreased appetiteMetabolism and nutrition disorders81/27122/135
Neutrophil count decreasedInvestigations75/2710/135
FatigueGeneral disorders69/27120/135
VomitingGastrointestinal disorders60/27113/135
DiarrhoeaGastrointestinal disorders54/2716/135
Blood bilirubin increasedInvestigations53/27112/135

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
<=18 years000
Between 18 and 65 years206103309
>=65 years653297
Age, Continuous
Age, Continuous(years)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
Median58 (26 to 81)56 (24 to 80)57 (24 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
Female10151152
Male17084254
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino271134405
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
American Indian or Alaska Native000
Asian271135406
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)TAS-102(Trifluridine/Tipiracil)PlaceboTotal
South Korea552681
China204101305
Thailand12820
08

Study locations

4 sites
  • Peking University Cancer Hospital
    Beijing, 100142, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Chulalongkorn University & The King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
09

References and documents

Publications

  • Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018 Feb 1;36(4):350-358. doi: 10.1200/JCO.2017.74.3245. Epub 2017 Dec 7. PubMed 29215955 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Feb 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2013
First posted
Oct 8, 2013
Start
Sep 2013
Primary completionActual
Feb 16, 2016
CompletionActual
Jun 30, 2016
Results first posted
Nov 17, 2020
Last update
Nov 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01955837
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Sep 2013
Primary completion
Feb 16, 2016
Completion
Jun 30, 2016
Results posted
Nov 17, 2020
Last update
Nov 17, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion